Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) Previously Treated With Unlimited Cytotoxic Chemotherapy Regimen (SPERA)

NCT00450970 is registered in ClinicalTrials.gov with Agennix as lead sponsor.

NCT NCT00450970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00450970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) Previously Treated With Unlimited Cytotoxic Chemotherapy Regimen (SPERA)
Lead sponsor
Agennix
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2007
Completion date
December 31, 2009
Enrollment
344 (actual)
Sites
121

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer